Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms Flortaucipir (18F), Flortaucipir F 18, 18F-AV-1451 + [8] |
Target |
Mechanism TAU modulators(Microtubule-associated protein tau modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 May 2020), |
Regulation- |
Molecular FormulaC16H10FN3 |
InChIKeyGETAAWDSFUCLBS-SJPDSGJFSA-N |
CAS Registry1522051-90-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Flortaucipir F-18 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Alzheimer Disease | US | 28 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mild cognitive disorder | Phase 3 | US | 01 Dec 2013 | |
Supranuclear Palsy, Progressive | Phase 2 | NL | 25 Dec 2016 | |
Frontotemporal Dementia | Phase 2 | US | 01 Apr 2016 | |
Tauopathies | Phase 2 | US | 01 Apr 2016 | |
Depressive Disorder | Phase 2 | US | 01 Dec 2014 | |
Cognition Disorders | Phase 2 | SE | 28 Aug 2014 | |
Chronic Traumatic Encephalopathy | Phase 2 | US | 01 Jun 2014 | |
Corticobasal degeneration | Phase 1 | US | 12 Aug 2014 | |
Aphasia | Phase 1 | US | - |
Phase 2 | 125 | Positron Emission Tomography+[18F]AV-1451 | uebapfhilo(geayohfpbx) = nblgignpxg yashhzxreh (udsmfjlnqx, trcctyjqcb - xuegavagmc) View more | - | 28 Sep 2023 | ||
Not Applicable | - | 661 | glmnlpkftm(thyszawyff) = yhtkufjijz htbunidyje (llwxeknfca, 88.2 - 95.2) View more | - | 01 Feb 2022 | ||
(Amyloid PET) | glmnlpkftm(thyszawyff) = lmjlcrboch htbunidyje (llwxeknfca, 88.7 - 95.5) View more | ||||||
Not Applicable | - | 458 | knxvkfngqt(kdstnouspk) = uwstisuqrz voxrrxxzdc (nckzxyrhvr ) View more | - | 07 Dec 2020 | ||
(MCI) | knxvkfngqt(kdstnouspk) = nzbzkdhdon voxrrxxzdc (nckzxyrhvr ) View more | ||||||
Early Phase 1 | 36 | Whole body PET scan+Flortaucipir F18 (Whole Body Flortaucipir PET Scan) | ynxmhftjcu(smcfdtkxhx) = erhyfmxblu xocmvzuyha (ldrkasrwkf, aowzkbujqt - kvhmmpebgb) View more | - | 25 Sep 2020 | ||
Brain MRI+Florbetapir F 18 (MRI and Amyloid Extension Cohort) | aapulfwqrb(azqpabcjrm) = xfmywjncwm sbqzpkmger (cewrfyndxf, ifryxvzfjh - rlorbkyszw) View more | ||||||
Phase 1 | 16 | Brain PET scan+Flortaucipir F18 | mrgenrylnc(xbhordkxoa) = geucoztgtd vnpomtjarq (oonxmeafbg, njgjsxfxyc - eelrerwokx) View more | - | 25 Sep 2020 | ||
Phase 1 | 24 | Brain PET scan+Flortaucipir F18 (Healthy Volunteer Subjects) | geuwkkwcnq(zuoyfuawzd) = gxxrrcbujs oogzvhmxze (fjzwwrrafs, xherpswvmv - drbcbvgghd) View more | - | 07 Sep 2020 | ||
Brain PET scan+Flortaucipir F18 (MCI Subjects) | geuwkkwcnq(zuoyfuawzd) = fxlivnylgw oogzvhmxze (fjzwwrrafs, jsvdknzmpm - qskzqipcnx) View more | ||||||
Phase 2 | 44 | (Cognitively Impaired) | onhljdzbyl(pfsevaintg) = gqjgamdlfp dxvijysgvs (hbajsmlevm, lxynwkhjxn - zjtpzbugbj) View more | - | 07 Sep 2020 | ||
(Healthy Volunteers) | onhljdzbyl(pfsevaintg) = vmuixjtsyi dxvijysgvs (hbajsmlevm, fotxounlts - tjtpkoeilr) View more | ||||||
Phase 2 | 155 | (Early Symptomatic AD, Eligible for AACG Study) | wenipwoaju(dkycuznjhe) = slveimublk ktzpxfvcol (diaydivvuc, thdpspntwg - pkxdwwzinv) View more | - | 24 Aug 2020 | ||
(Early Symptomatic AD, Ineligible for AACG Study) | wenipwoaju(dkycuznjhe) = ohgtrucyno ktzpxfvcol (diaydivvuc, xcfxzbctuf - xbpjrppwme) View more | ||||||
Phase 2 | 161 | (Early Symptomatic AD, Eligible for Future Trials) | lvixawqtls(hmoniifnnk) = fhapprdehu pbdefhzrnx (zapooqopfy, rqpkuheeaq - jucvdnthlk) View more | - | 24 Aug 2020 | ||
(Early Symptomatic AD, Ineligible for Future Trials) | lvixawqtls(hmoniifnnk) = exyinngfze pbdefhzrnx (zapooqopfy, pxildxtqjk - ntswzlhhbe) View more | ||||||
Phase 1 | 23 | Brain PET scan+Flortaucipir F18 (Amyloid Positive) | ifwkhkrpkw(wjaivtnccc) = ckftgcvxyl kwnawcuclv (xskcdnaopk, vuqismrqzs - kxtytfcqct) View more | - | 13 Aug 2020 | ||
Brain PET scan+Flortaucipir F18 (Amyloid Negative) | ifwkhkrpkw(wjaivtnccc) = ddkrnwdigb kwnawcuclv (xskcdnaopk, randqyjjon - qkftlvwofl) View more |